Skip to main content
. Author manuscript; available in PMC: 2023 May 26.
Published in final edited form as: Mol Pharm. 2022 Feb 18;19(3):974–984. doi: 10.1021/acs.molpharmaceut.1c00944

Figure 8.

Figure 8.

LL-37 expression of (A) HL60, (B) U937, (C) HaCaT cells after treatment with different nanofiber formulations for 1, 3, and 5 days. Blank control: no treatment. VD3: free 1,25(OH)2D3. VD3/VID400: free 1,25(OH)2D3 and VID400. F127/PCL: PCL/pluronic F-127 blend nanofibers. F127/PCL/VD3: 1,25(OH)2D3 loaded PCL/pluronic F-127 blend nanofibers. F127/PCL/VD3/VID400: 1,25(OH)2D3 and VID400 coloaded PCL/pluronic F-127 blend nanofibers. (*p<0.05)